Suppr超能文献

新型蒽环类药物DA - 125在静脉注射给硝酸铀酰诱导的急性肾衰竭大鼠或蛋白质 - 热量营养不良大鼠后的药代动力学。

Pharmacokinetics of DA-125, a new anthracycline, after intravenous administration to uranyl nitrate-induced acute renal failure rats or protein-calorie malnutrition rats.

作者信息

Kim Y G, Yoon E J, Yoon W H, Shim H J, Lee S D, Kim W B, Yang J, Lee M G

机构信息

College of Pharmacy, Seoul National University, Korea.

出版信息

Biopharm Drug Dispos. 1996 Apr;17(3):183-95. doi: 10.1002/(SICI)1099-081X(199604)17:3<183::AID-BDD955>3.0.CO;2-M.

Abstract

The pharmacokinetics of DA-125 were compared after intravenous (i.v.) administration of the drug, 10 mg kg-1, to control male Sprague-Dawley rats (n = 9) and uranyl nitrate-induced acute renal failure (U-ARF, n = 12) rats, or male Sprague-Dawley rats fed on a 23% (control, n = 8) or a 5% (protein-calorie malnutrition, PCM, n = 9) protein diet. After i.v. administration of DA-125, almost 'constant' plasma concentrations of M1, M2, and M4 were maintained from 1-2 h to 8-10 h in all rat groups due to the continuous formation of M2 from M1 and M4 from M3. The plasma concentrations of M3 were the lowest among M1-M4 for all rat groups due to the rapid and almost complete conversion of M3 to M4 and other metabolite(s). The AUCt values of M1 (115 against 82.5 micrograms min mL-1), M2 (33.0 against 23.6 micrograms min mL-1), and M4 (26.3 against 15.1 micrograms min mL-1) were significantly higher in the U-ARF rats than in the control rats. The percentages of i.v. dose excreted in 24 h urine as M1 (under the detection limit against 0.316%), M2 (under the detection limit against 5.58%), and M4 (0.0174 against 0.719%)--expressed in terms of DA-125--were significantly lower in the U-ARF rats than in the control rats, and this could be due to the decreased kidney function in the U-ARF rats. However, the percentages of i.v. dose recovered from the GI tract at 24 h as M1 (0.0532% against under the detection limit), M3 (0.0286% against under the detection limit), and M4 (0.702% against 0.305%)--expressed in terms of DA-125--were significantly greater in the U-ARF rats than in the control rats. All U-ARF rats had ascites, but the concentrations of M1 (0.0320 micrograms mL-1), M2 (0.0265 micrograms mL-1), M3 (under the detection limit), and M4 (0.032 micrograms mL-1) in the ascites from one rat were almost negligible. The plasma concentrations and most of the pharmacokinetic parameters of M1, M2, and M4 were not significantly different between the PCM rats and their control rats.

摘要

将10mg/kg的药物DA - 125静脉注射给雄性Sprague - Dawley对照大鼠(n = 9)、硝酸铀酰诱导的急性肾衰竭(U - ARF,n = 12)大鼠,或喂食23%(对照,n = 8)或5%(蛋白质 - 热量营养不良,PCM,n = 9)蛋白质饮食的雄性Sprague - Dawley大鼠后,比较了DA - 125的药代动力学。静脉注射DA - 125后,由于M1持续形成M2以及M3持续形成M4,所有大鼠组在1 - 2小时至8 - 10小时内M1、M2和M4的血浆浓度几乎保持“恒定”。在所有大鼠组中,M3的血浆浓度在M1 - M4中是最低的,这是因为M3迅速且几乎完全转化为M4和其他代谢物。U - ARF大鼠中M1(115对82.5微克·分钟·毫升-1)、M2(33.0对23.6微克·分钟·毫升-1)和M4(26.3对15.1微克·分钟·毫升-1)的AUCt值显著高于对照大鼠。以DA - 125计,U - ARF大鼠24小时尿液中以M1(低于检测限对0.316%)、M2(低于检测限对5.58%)和M4(0.0174对0.719%)形式排泄的静脉注射剂量百分比显著低于对照大鼠,这可能是由于U - ARF大鼠肾功能下降所致。然而,以DA - 125计,U - ARF大鼠24小时从胃肠道回收的静脉注射剂量百分比,以M1(0.0532%对低于检测限)、M3(0.0286%对低于检测限)和M4(0.702%对0.305%)形式表示的,显著高于对照大鼠。所有U - ARF大鼠都有腹水,但一只大鼠腹水中M1(0.0320微克·毫升-1)、M2(0.0265微克·毫升-1)、M3(低于检测限)和M4(0.032微克·毫升-1)的浓度几乎可以忽略不计。PCM大鼠与其对照大鼠之间,M1、M2和M4的血浆浓度以及大多数药代动力学参数没有显著差异。

相似文献

1
2
Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine.
Biopharm Drug Dispos. 1996 Jul;17(5):373-420. doi: 10.1002/(SICI)1099-081X(199607)17:5<373::AID-BDD373>3.0.CO;2-U.
4
Effects of acute renal failure on the pharmacokinetics of DA-7867, a new oxazolidinone, in rats.
Biopharm Drug Dispos. 2006 Jan;27(1):29-37. doi: 10.1002/bdd.478.

引用本文的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验